Payment overview · 2025
General Payments
$1,319.82
77 reported records · 19 companies
Healthcare provider profile · identity verified
Joseph A Larakers, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALICE, TX · NPI 1023057270
Verified facts
What the public records show
CMS Open Payments records show Joseph A Larakers, M.D. received $1,319.82 in general payments during 2025 across 77 reported records.
Novo Nordisk Inc accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Otezla, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $266.46 | 20.2% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $188.14 | 14.2% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.88 | 11.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $135.46 | 10.3% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $72.28 | 5.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.26 | 5.5% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.52 | 4.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.36 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.35 | 3.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.45 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.47 | 3.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.39 | 3.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.30 | 3.2% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $24.41 | 1.9% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $21.48 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.42 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.60 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.47 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,319.82 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $237.46 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $176.05 | 17 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.27 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $135.46 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.49 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.44 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $87.75 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $72.28 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.26 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.52 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $52.36 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.39 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.00 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $12.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 242 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 258 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 181 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 424 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 64 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 164 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
230 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
242 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
258 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
164 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
258 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
181 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
207 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
424 | 74 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1336 | 294 |
| Amlodipine Besylate | Amlodipine Besylate | 1335 | 297 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1309 | 247 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1299 | 303 |
| Gabapentin | Gabapentin | 1066 | 225 |
| Pantoprazole Sodium | Pantoprazole Sodium | 936 | 210 |
| Metformin Hcl | Metformin Hcl | 870 | 206 |
| Metoprolol Succinate | Metoprolol Succinate | 823 | 193 |
| Furosemide | Furosemide | 732 | 170 |
| Losartan Potassium | Losartan Potassium | 731 | 178 |
| Lisinopril | Lisinopril | 670 | 167 |
| Tramadol Hcl | Tramadol Hcl | 655 | 117 |
| Potassium Chloride | Potassium Chloride | 617 | 131 |
| Tamsulosin Hcl | Tamsulosin Hcl | 497 | 135 |
| Trazodone Hcl | Trazodone Hcl | 482 | 96 |
| Donepezil Hcl | Donepezil Hcl | 446 | 80 |
| Omeprazole | Omeprazole | 432 | 94 |
| Ozempic | Semaglutide | 424 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 414 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 407 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 387 | 85 |
| Simvastatin | Simvastatin | 385 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 381 | 130 |
| Hydrochlorothiazide | Hydrochlorothiazide | 350 | 79 |
| Eliquis | Apixaban | 327 | 73 |
| Famotidine | Famotidine | 327 | 77 |
| Tizanidine Hcl | Tizanidine Hcl | 325 | 82 |
| Celecoxib | Celecoxib | 317 | 72 |
| Montelukast Sodium | Montelukast Sodium | 310 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 307 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 301 | 65 |
| Memantine Hcl | Memantine Hcl | 296 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 290 | 58 |
| Divalproex Sodium | Divalproex Sodium | 281 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 280 | 92 |
| Pregabalin | Pregabalin | 264 | 49 |
| Jardiance | Empagliflozin | 258 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 253 | 59 |
| Farxiga | Dapagliflozin Propanediol | 242 | 54 |
| Carvedilol | Carvedilol | 239 | 56 |
| Mirtazapine | Mirtazapine | 236 | 43 |
| Myrbetriq | Mirabegron | 230 | 32 |
| Glipizide | Glipizide | 223 | 57 |
| Sertraline Hcl | Sertraline Hcl | 213 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 211 | 53 |
| Valsartan | Valsartan | 211 | 58 |
| Alprazolam | Alprazolam | 208 | 49 |
| Trulicity | Dulaglutide | 207 | 42 |
| Allopurinol | Allopurinol | 202 | 46 |
| Spironolactone | Spironolactone | 198 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 49 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 194 | 51 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 189 | 40 |
| Mounjaro | Tirzepatide | 181 | 38 |
| Meloxicam | Meloxicam | 178 | 32 |
| Buspirone Hcl | Buspirone Hcl | 175 | 33 |
| Januvia | Sitagliptin Phosphate | 175 | 16 |
| Ezetimibe | Ezetimibe | 173 | 31 |
| Irbesartan | Irbesartan | 173 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 165 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 164 | 25 |
| Alendronate Sodium | Alendronate Sodium | 154 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 150 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 148 | 24 |
| Nystatin | Nystatin | 143 | 57 |
| Prednisone | Prednisone | 141 | 74 |
| Methocarbamol | Methocarbamol | 139 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 135 | 30 |
| Levetiracetam | Levetiracetam | 135 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 126 | 81 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 122 | 73 |
| Fluoxetine Hcl | Fluoxetine Hcl | 122 | 26 |
| Azithromycin | Azithromycin | 114 | 97 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 114 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 114 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 100 | 26 |
| Latanoprost | Latanoprost | 97 | 15 |
| Tradjenta | Linagliptin | 96 | 12 |
| Hydrocortisone | Hydrocortisone | 95 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 16 |
| Glimepiride | Glimepiride | 92 | 25 |
| Temazepam | Temazepam | 92 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 91 | 13 |
| Finasteride | Finasteride | 90 | 22 |
| Baclofen | Baclofen | 87 | 15 |
| Clonazepam | Clonazepam | 86 | 17 |
| Lorazepam | Lorazepam | 86 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 78 | 15 |
| Metformin Hcl Er | Metformin Hcl | 78 | 26 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 76 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 16 |
| Cephalexin | Cephalexin | 70 | 14 |
| Meclizine Hcl | Meclizine Hcl | 70 | 13 |
| Terazosin Hcl | Terazosin Hcl | 70 | 15 |
| Digoxin | Digoxin | 69 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 29 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 67 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 25 |
| Nitroglycerin | Nitroglycerin | 66 | 45 |
| Xarelto | Rivaroxaban | 65 | 17 |
| Atenolol | Atenolol | 64 | 11 |
| Ondansetron Odt | Ondansetron | 64 | 40 |
| Rybelsus | Semaglutide | 64 | 11 |
| Topiramate | Topiramate | 64 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 63 | 17 |
| Ibuprofen | Ibuprofen | 61 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 17 |
| Nifedipine Er | Nifedipine | 59 | 12 |
| Propranolol Hcl | Propranolol Hcl | 57 | 12 |
| Fenofibrate | Fenofibrate | 56 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Enulose | Lactulose | 51 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 51 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 12 |
| Levofloxacin | Levofloxacin | 49 | 41 |
| Lovastatin | Lovastatin | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 46 | 11 |
| Labetalol Hcl | Labetalol Hcl | 46 | suppressed |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 38 |
| Cefuroxime | Cefuroxime Axetil | 43 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 43 | suppressed |
| Linzess | Linaclotide | 43 | 11 |
| Risperidone | Risperidone | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 40 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 41 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Metolazone | Metolazone | 38 | 12 |
| Naproxen | Naproxen | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 14 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Nyamyc | Nystatin | 33 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 16 |
| Acarbose | Acarbose | 30 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 18 |
| Lactulose | Lactulose | 29 | 15 |
| Sulfasalazine | Sulfasalazine | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 14 |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Mupirocin | Mupirocin | 23 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 13 |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Cholestyramine Light | Cholestyramine | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Sulindac | Sulindac | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Constulose | Lactulose | 17 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,319.82 · 77 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BEYFORTUS, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, VAXELIS, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error